Evercore ISI Group Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Positive 87.3%

Neg 0% Neu 0% Pos 87.3%

Evercore ISI Group analyst Cory Kasimov initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $50.